Entero Therapeutics, Stock Buy Hold or Sell Recommendation
| ENTO Stock | 0.42 0.02 5.00% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Entero Therapeutics, is 'Strong Sell'. The recommendation algorithm takes into account all of Entero Therapeutics,'s available fundamental, technical, and predictive indicators you will find on this site.
Check out Entero Therapeutics, Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Entero Stock, please use our How to Invest in Entero Therapeutics, guide. In addition, we conduct extensive research on individual companies such as Entero and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Entero Therapeutics,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
Entero |
Execute Entero Therapeutics, Buy or Sell Advice
The Entero recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Entero Therapeutics,. Macroaxis does not own or have any residual interests in Entero Therapeutics, or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Entero Therapeutics,'s advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Insignificant | Details | |
Volatility | Risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Entero Therapeutics, Trading Alerts and Improvement Suggestions
| Entero Therapeutics, is way too risky over 90 days horizon | |
| Entero Therapeutics, has some characteristics of a very speculative penny stock | |
| Entero Therapeutics, appears to be risky and price may revert if volatility continues | |
| Entero Therapeutics, has a very high chance of going through financial distress in the upcoming years | |
| Entero Therapeutics, was previously known as First Wave BioPharma and was traded on NASDAQ Exchange under the symbol FWBI. | |
| Net Loss for the year was (15.79 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Entero Therapeutics, generates negative cash flow from operations | |
| Entero Therapeutics, has a frail financial position based on the latest SEC disclosures | |
| Latest headline from investing.com: Zenas BioPharma CEO Leon O. Moulder Jr. acquires shares worth 148,925 |
Entero Therapeutics, current analysts advice
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Entero analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Entero analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.
Entero Therapeutics, Returns Distribution Density
The distribution of Entero Therapeutics,'s historical returns is an attempt to chart the uncertainty of Entero Therapeutics,'s future price movements. The chart of the probability distribution of Entero Therapeutics, daily returns describes the distribution of returns around its average expected value. We use Entero Therapeutics, price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Entero Therapeutics, returns is essential to provide solid investment advice for Entero Therapeutics,.
| Mean Return | 1.02 | Value At Risk | -13.33 | Potential Upside | 24.44 | Standard Deviation | 12.83 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Entero Therapeutics, historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Entero Therapeutics, Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Entero Therapeutics, or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Entero Therapeutics,'s price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Entero stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.71 | |
β | Beta against Dow Jones | 3.46 | |
σ | Overall volatility | 12.42 | |
Ir | Information ratio | 0.07 |
Entero Therapeutics, Volatility Alert
Entero Therapeutics, is displaying above-average volatility over the selected time horizon. Entero Therapeutics, is a potential penny stock. Although Entero Therapeutics, may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Entero Therapeutics,. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Entero instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Entero Therapeutics, Fundamentals Vs Peers
Comparing Entero Therapeutics,'s fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Entero Therapeutics,'s direct or indirect competition across all of the common fundamentals between Entero Therapeutics, and the related equities. This way, we can detect undervalued stocks with similar characteristics as Entero Therapeutics, or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Entero Therapeutics,'s fundamental indicators could also be used in its relative valuation, which is a method of valuing Entero Therapeutics, by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Entero Therapeutics, to competition |
| Fundamentals | Entero Therapeutics, | Peer Average |
| Return On Equity | -0.15 | -0.31 |
| Return On Asset | -0.27 | -0.14 |
| Current Valuation | 66.34 M | 16.62 B |
| Shares Outstanding | 3.25 M | 571.82 M |
| Shares Owned By Insiders | 7.20 % | 10.09 % |
| Shares Owned By Institutions | 5.98 % | 39.21 % |
| Number Of Shares Shorted | 94.02 K | 4.71 M |
| Price To Book | 0.07 X | 9.51 X |
| EBITDA | (15.74 M) | 3.9 B |
| Net Income | (15.79 M) | 570.98 M |
| Total Debt | 826.84 K | 5.32 B |
| Book Value Per Share | 7.99 X | 1.93 K |
| Cash Flow From Operations | (12.38 M) | 971.22 M |
| Short Ratio | 0.06 X | 4.00 X |
| Earnings Per Share | (11.04) X | 3.12 X |
| Target Price | 36.0 | |
| Number Of Employees | 9 | 18.84 K |
| Beta | 1.37 | -0.15 |
| Market Capitalization | 1.11 M | 19.03 B |
| Total Asset | 6.88 M | 29.47 B |
| Retained Earnings | (184.33 M) | 9.33 B |
| Working Capital | 1.82 M | 1.48 B |
| Net Asset | 6.88 M |
Note: Acquisition by Khosla Chaitan Phd of 24889 shares of Entero Therapeutics, subject to Rule 16b-3 [view details]
Entero Therapeutics, Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Entero . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Entero Therapeutics, Buy or Sell Advice
When is the right time to buy or sell Entero Therapeutics,? Buying financial instruments such as Entero Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Entero Therapeutics, in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Small Blend Funds Thematic Idea Now
Small Blend Funds
Fund or Etfs that invest in stocks of small to mid-sized entities that have characteristics of both growth and value companies. The Small Blend Funds theme has 48 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Small Blend Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Entero Therapeutics, Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Entero Stock, please use our How to Invest in Entero Therapeutics, guide.You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Entero Therapeutics,. If investors know Entero will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Entero Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (11.04) | Return On Assets (0.27) | Return On Equity (0.15) |
The market value of Entero Therapeutics, is measured differently than its book value, which is the value of Entero that is recorded on the company's balance sheet. Investors also form their own opinion of Entero Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Entero Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Entero Therapeutics,'s market value can be influenced by many factors that don't directly affect Entero Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Entero Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Entero Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Entero Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.